A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients

Clinical Therapeutics

Volumn 32, Issue 12, 2010, Pages 2012-2023

  Kuypers, Dirk R J ^a   de Jonge, Hylke ^a   Naesens, Maarten ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

ABCB1; CYP3A4; CYP3A5; Delayed graft function; New onset diabetes after transplantation; NODAT; P glycoprotein; Pharmacokinetics; Posttransplantation diabetes mellitus; PTDM; Renal transplantation; Single nucleotide polymorphisms; Tacrolimus; Tacrolimus toxicity

Indexed keywords

CYTOCHROME P450 3A5; GENOMIC DNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG DOSE REDUCTION; EVENING DOSAGE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CYTOCHROME P-450 CYP3A; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 78649575551     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.11.010     Document Type: Article

References (48)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007, 357:2562-2575. ELITE-Symphony Study.
2. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995, 29:404-430.
3. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmaco-kinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004, 43:741-762.
4. Masuda S, Inui K An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006, 112:184-198.
5. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995, 23:1315-1324.
6. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005, 51:1374-1381.
7. 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999, 27:633-636.
8. Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009, 20:2269-2276.
9. Sun H, Frassetto LA, Huang Y, Benet LZ Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010, 87:465-472.
10. Yarlagadda SG, Coca SG, Formica RN, et al. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant. 2009, 24:1039-1047.
11. Perico N, Cattaneo D, Sayegh MH, Remuzzi G Delayed graft function in kidney transplantation. Lancet 2004, 364:1814-1827.
12. Okabe H, Hashimoto Y, Inui KI Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol. 2000, 52:1467-1472.
13. Ekbal NJ, Holt DW, Macphee IA Pharmacogenetics of immunosuppressive drugs: Prospect of individual therapy for transplant patients. Pharmacogenomics 2008, 9:585-596.
14. Coto E, Tavira B Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009, 88(Suppl 3):S62-S67.
15. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008, 18:861-868.
16. Roberts PJ, Rollins KD, Kashuba AD, et al. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos. 2008, 36:1465-1469.
17. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit. 2009, 31:139-152.
18. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008, 8:753-760.
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5-S20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
20. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplanta- tion: 2003 International consensus guidelines. Proceedings of an International expert panel meeting. Barcelona, Spain, February 19, 2003. Transplantation 2003, 75:SS3-SS24. Interna- tional Expert Panel.
21. Miller SA, Dykes DD, Polesky HF A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1998, 16:1215.
22. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drugrelated nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007, 82:711-725.
23. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004, 78:1182-1187.
24. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [published correction appears in Clin Pharmacol Ther. 2004;75: 124]. Clin Pharmacol Ther. 2001, 69:169-174.
25. Cavalli SA, Hirata MH, Hirata RD Detection of Mboll polymorphism at the 5'promoter region of CYP3A4. Clin Chem. 2001, 47:348-351.
26. Kirkwood BR, Sterne JA Essential Medical Statistics 2003, Blackwell Science, Malden, Mass. 2nd ed.
27. Broad Institute Software, Accessed November 9, 2010. http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/downloads.
28. Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006, 6:1042-1048.
29. Andrés A., Budde K, Clavien PA, et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation 2009, 88:1101-1108. SENIOR Study Team.
30. Cransberg K, Bouts AH, Cornelissen EA, et al. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine. Transplantation 2008, 86:1199-1205.
31. Veau C, Leroy C, Banide H, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 2001, 16:1607-1614.
32. Guévin C, Michaud J, Naud J, et al. Down-regulation of hepatic cyto- chrome p450 in chronic renal failure: Role of uremic mediators. Br J Pharmacol. 2002, 137:1039-1046.
33. Lam JL, Okochi H, Huang Y, Benet LZ In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporterenzyme interplay. Drug Metab Dispos. 2006, 34:1336-1344.
34. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 2005, 5:2236-2243.
35. Chandel N, Aggarwal PK, Minz M, et al. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009, 19:458-463.
36. Isoherranen N, Ludington SR, Givens RC, et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: An in vitro-in vivo evaluation. Drug Metab Dispos 2008, 36:146-154.
37. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002, 74:1419-1424.
38. van Duijnhoven EM, Boots JM, Christiaans MH, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003, 16:721-725.
39. Kishino S, Takekuma Y, Sugawara M, et al. Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. Clin Transplant 2003, 17:412-416.
40. de Mattos AM, Olyaei AJ, Prather JC, et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int. 2005, 67:714-720.
41. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus [published correction appears in Am J Transplant. 2008;8:908]. Am J Transplant 2007, 7:1506-1514. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral Monitoring Versus Tacrolimus) Investigators.
42. Bloom RD, Crutchlow MF Newonset diabetes mellitus in the kidney recipient: Diagnosis and management strategies. Clin J Am Soc Nephrol. 2008, 3(Suppl 2):S38-S48.
43. Rodrigo E, Piñera C, de Cos MA, et al. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation. Transpl Int. 2005, 18:1152-1157.
44. Kuypers DR, Claes K, Bammens B, et al. Early clinical assessment of glucose metabolism in renal allograft recipients: Diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant 2008, 23:2033-2042.
45. Massry SG Insulin secretion in uremia. Am J Kidney Dis. 2001, 38(Suppl 1):S58-S62.
46. Rigalleau V, Gin H Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care 2005, 8:463-469.
47. Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
48. Fuji S, Kim SW, Mori S, et al. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2010, 45:405-406.